Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could improve the prognosis of patients with EGFR-mutated non-small cell lung cancer (NSCLC). With the application of TKIs, gene detection found that more and more patients were with EGFR T790M mutations, which significantly affect the treatment and prognosis of NSCLC patients. This article reviews the relation between T790M mutation and EGFR-TKIs, evaluates the population characteristics of primary T790M mutation and the efficacy and prognosis of EGFR-TKIs treatment, as well as pays attention to the new secondary drug resistance of the third generation of EGFR-TKIs, to provide clinical basis and ideas for the precise treatment of NSCLC.